Details on All 41 Patients
| Patient no. | Disease | Mass lesion | Tissue | SUV | Residual 18F-FDG activity | ||
|---|---|---|---|---|---|---|---|
| Bladder | Ureter | ||||||
| 1 | UCer | Primary lesion | SCC | 2.09 | − | − | |
| 2 | UCer | Primary lesion | SCC | 3.41 | − | + | |
| 3 | UCer | Primary lesion | SCC | 4.35 | − | − | |
| 4 | UCer | Primary lesion | SCC | 4.35 | − | − | |
| 5 | UCer | Primary lesion | SCC | 4.82 | − | − | |
| 6 | UCer | Primary lesion | SCC | 5.96 | − | − | |
| 7 | UCer | Primary lesion | SCC | 6.56 | − | + | |
| 8 | UCer | Primary lesion | SCC | 7.19 | − | − | |
| 9 | UCer | Primary lesion | SCC | 7.56 | − | + | |
| 10 | UCer | Primary lesion | SCC | 7.97 | − | − | |
| 11 | UCer | Primary lesion | SCC | 8.15 | − | − | |
| 12 | UCer | Primary lesion | SCC | 10.83 | − | − | |
| 13 | UCer | Primary lesion | SCC | 11.00 | − | − | |
| 14 | UCer | Primary lesion | SCC | 11.53 | − | − | |
| 15 | UCer | Primary lesion | SCC | 13.58 | − | + | |
| 16 | RUCer | Local recurrence | SCC | 2.14 | − | − | |
| 17 | RUCer | Local recurrence | Clear cell adenocarcinoma | 2.14 | − | − | |
| 18 | RUCer | Local recurrence | SCC | 2.29 | − | − | |
| 19 | RUCer | Local recurrence | SCC | 2.83 | − | − | |
| 20 | RUCer | Local recurrence | SCC | 3.10 | − | − | |
| 21 | NRUCer | Pelvic cavity | Diagnosed by clinical course | 0.26 | − | − | |
| 22 | NRUCer | Local lesion | Diagnosed by clinical course | 1.69 | − | − | |
| 23 | NRUCer | Local lesion | No malignancy | 1.95 | + | − | |
| 24 | UCor | Primary lesion | Adenocarcinoma | 2.64 | − | + | |
| 25 | UCor | Primary lesion | Endometrioid adenocarcinoma | 2.74 | − | − | |
| 26 | UCor | Primary lesion | Adenocarcinoma | 4.77 | − | − | |
| 27 | UCor | Primary lesion | Endometrioid adenocarcinoma | 4.93 | − | − | |
| 28 | UCor | Primary lesion | Adenocarcinoma | 7.50 | − | − | |
| 29 | UCor | Primary lesion | Endometrioid adenocarcinoma | 10.06 | − | − | |
| 30 | RUCor | Local recurrence | Metastatic adenocarcinoma | 7.60 | − | − | |
| 31 | RUCor | Local recurrence | Endometrioid adenocarcinoma | 11.20 | − | − | |
| 32 | OC | Primary lesion | Serous cystadenocarcinoma | 6.36 | − | − | |
| 33 | ROC | Remaining ovary | Yolk sac tumor recurrence | 2.60 | + | − | |
| 34 | ROC | Lymph node | Endometrioid adenocarcinoma | 5.84 | − | − | |
| 35 | ROC | Lymph node | Mucinous cystadenocarcinoma | 8.55 | − | − | |
| 36 | ROC | Lymph node | Mucinous cystadenocarcinoma | 3.53 | − | − | |
| 37 | ROC | Lymph node | Clear cell carcinoma | 5.11 | − | − | |
| 38 | BO | Primary lesion | Dermoid cyst | 1.37 | − | + | |
| 39 | BO | Primary lesion | Fibroma | 3.93 | − | − | |
| 40 | BO | Remaining ovary | No malignancy | 1.17 | − | − | |
| 41 | BO | Remaining ovary | No malignancy | 1.63 | − | − | |
UCer = uterine cervical carcinoma; SCC = squamous cell carcinoma; RUCer = recurrent uterine cervical carcinoma; NRUCer = nonrecurrent uterine cervical carcinoma; UCor = uterine corpus carcinoma; RUCor = recurrent uterine corpus carcinoma; OC = ovarian cancer; ROC = recurrent ovarian cancer; BO = benign ovarian tumor or no malignancy.